Genera Biosystems Ltd (GBI)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Genera Biosystems Ltd (GBI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013542
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:22
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オーストラリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Genera Biosystems Ltd (GBL) is a developer and commercializer of multiplexed molecular diagnostic testing products. The company offers RTIplex and PapType molecular diagnostic test. Its RTIplex is a multiplexed and automated PCR based test for detection of viral and bacterial respiratory pathogens; and PapType is a molecular diagnostic test for the detection and genotyping of high risk and low risk types of human papillomavirus that cause cervical cancer or genital warts. GBL uses AmpaSand beads technology to create identifiable clusters of beads which can be distinguished in a conventional flow cytometer. The company provides products to detect influenzaA, influenzaB, influenza A H1N1, influenzaA H5N1, respiratory syncytial virus, human metapneumovirus, adenovirus, rhinovirus, bordetella pertussis, and chlamydophila pneumonia. It collaborates with pathology customers and IVD companies. GBL is headquartered in Melbourne, Victoria, Australia.

Genera Biosystems Ltd (GBI) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Genera Biosystems Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Genera Biosystems Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Genera Biosystems Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Genera Biosystems Ltd, Medical Devices Deals, 2011 to YTD 2017 8
Genera Biosystems Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Genera Biosystems Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Equity Offering 10
Genera Biosystems Announces Private Placement of Shares for USD0.5 Million 10
Genera Biosystems Completes Private Placement Of Shares For US$0.12 Million 11
Genera Biosystems Announces Rights Issue Of Shares For US$1.1 Million 12
Debt Offering 13
Genera Biosystems Completes Private Placement of Notes for USD0.3 Million 13
Genera Biosystems Raises USD0.2 Million in Private Placement of Notes Due 2015 14
Genera Biosystems Completes Private Placement Of Notes Due 2015 For US$0.34 Million 15
Genera Biosystems Ltd – Key Competitors 16
Genera Biosystems Ltd – Key Employees 17
Genera Biosystems Ltd – Locations And Subsidiaries 18
Head Office 18
Recent Developments 19
Financial Announcements 19
Oct 03, 2016: Genera Biosystems: 2016 Annual Report Highlights 19
Other Significant Developments 21
Nov 15, 2016: Genera Lodges 2016 Tax Return – To Receive $752k R&D Tax Rebate 21
Appendix 22
Methodology 22
About GlobalData 22
Contact Us 22
Disclaimer 22

List of Tables
Genera Biosystems Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Genera Biosystems Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 2
Genera Biosystems Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Genera Biosystems Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Genera Biosystems Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Genera Biosystems Ltd, Medical Devices Deals, 2011 to YTD 2017 8
Genera Biosystems Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Genera Biosystems Announces Private Placement of Shares for USD0.5 Million 10
Genera Biosystems Completes Private Placement Of Shares For US$0.12 Million 11
Genera Biosystems Announces Rights Issue Of Shares For US$1.1 Million 12
Genera Biosystems Completes Private Placement of Notes for USD0.3 Million 13
Genera Biosystems Raises USD0.2 Million in Private Placement of Notes Due 2015 14
Genera Biosystems Completes Private Placement Of Notes Due 2015 For US$0.34 Million 15
Genera Biosystems Ltd, Key Competitors 16
Genera Biosystems Ltd, Key Employees 17

★海外企業調査レポート[Genera Biosystems Ltd (GBI)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • ManpowerGroup Inc (MAN):企業の財務・戦略的SWOT分析
    ManpowerGroup Inc (MAN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Bio-Rad Laboratories Inc (BIO):企業の財務・戦略的SWOT分析
    Bio-Rad Laboratories Inc (BIO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • RCR Tomlinson Ltd (RCR):企業の財務・戦略的SWOT分析
    RCR Tomlinson Ltd (RCR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • NORDSEE GmbH.:戦略・SWOT・企業財務分析
    NORDSEE GmbH. - Strategy, SWOT and Corporate Finance Report Summary NORDSEE GmbH. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Yissum Research Development Company of the Hebrew University of Jerusalem Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Yissum Research Development Company of the Hebrew University of Jerusalem Ltd (YRDC) is a technology transfer company that offers marketing the inventions and know-how generated by the University's researchers and students. The company’s products include exelon, doxil, cherry tomatoes and lo …
  • Epigenomics AG (ECX):製薬・医療:M&Aディール及び事業提携情報
    Summary Epigenomics AG (Epigenomics) is a molecular diagnostics company which develops and commercializes in-vitro diagnostic (IVD) tests for screening, early detection and diagnosis of cancer. Its lead product, Epi proColon is a blood-based test for rapid detection of colorectal cancer; and Epi pro …
  • Canadian Natural Resources Ltd Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    Canadian Natural Resources Ltd Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary Canadian Natural Resources Ltd (Canadian Natural) is an independent upstream oil and gas company. The company carries out acquisition, exploration, development, production, marketing a …
  • Baytex Energy Corp (BTE):企業の財務・戦略的SWOT分析
    Baytex Energy Corp (BTE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • IDEXX Laboratories, Inc.:企業の戦略・SWOT・財務情報
    IDEXX Laboratories, Inc. - Strategy, SWOT and Corporate Finance Report Summary IDEXX Laboratories, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Jack Henry & Associates, Inc.:戦略・SWOT・企業財務分析
    Jack Henry & Associates, Inc. - Strategy, SWOT and Corporate Finance Report Summary Jack Henry & Associates, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Vertex Pharmaceuticals Inc (VRTX):企業の財務・戦略的SWOT分析
    Vertex Pharmaceuticals Inc (VRTX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Admedes GmbH:企業の戦略的SWOT分析
    Admedes GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Elektrani na Makedonija:企業の戦略的SWOT分析
    Elektrani na Makedonija - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • S&T Dynamics Co., Ltd.:戦略・SWOT・企業財務分析
    S&T Dynamics Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary S&T Dynamics Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Kallpa Generacion SA:企業の戦略的SWOT分析
    Kallpa Generacion SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Companhia de Saneamento Basico do Estado de Sao Paulo (SBSP3):企業の財務・戦略的SWOT分析
    Summary Companhia de Saneamento Basico do Estado de Sao Paulo (SABESP) is an environmental consulting company that is responsible for supplying water and collecting and treating sewage in municipalities of Sao Paulo state. The company provides water and sewage services in another four municipalities …
  • Leonardo SpA (LDO):企業の財務・戦略的SWOT分析
    Leonardo SpA (LDO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • PT Elnusa Tbk (ELSA):企業の財務・戦略的SWOT分析
    Summary PT Elnusa Tbk (PT Elnusa), a subsidiary of PT Pertamina (Persero), is an oil and gas company that offers geo science services, and drilling and oilfield services. The company's geo science services include seismic data acquisition, seismic data measurement, seismic data processing, and non s …
  • Vita 34 AG (V3V):製薬・医療:M&Aディール及び事業提携情報
    Summary Vita 34 AG (Vita 34), formerly Vita 34 International AG, is an umbilical cord blood bank that collects, prepares, processes, deposits, and stores stem cells from umbilical cord blood. The company's products comprise vitaplus, vitaplus25, vitaplus50, vitapluscordtissue, vitapluscordtissue25, …
  • TOA OIL Co Ltd (5008):企業の財務・戦略的SWOT分析
    Summary TOA OIL Co Ltd (TOA OIL), a subsidiary of Showa Shell Sekiyu KK is an oil and gas company that offers contract refining of crude oil. The company offers products such as diesel oil, coker naphtha scrubber, kerosene, polynaphtha units, LPG hydrofining unit, gasoline scrubber, and vacuum diese …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆